Parrillo Je,Parker Mm,Natanson C.Septic Shock: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.Ann Intern Med. 1990;113:227-242
2.
Niederman Ms,Fein Am.Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: A common clinical sequence.Clin Chest Med. 1990;11:633-650
3.
Parker Mm,Parrillo Je..Septic shock: Hemodynamics and pathogenesis.JAMA. 1983;250:3324-8
4.
Wolff Sm,Bennett Jv..Gram negative rod bacteremia.N Engl J Med. 1974;291:733-8
5.
Scheckler We..Septicemia and nosocomial infections in a community hospital.Ann Inter Med. 1978;89:754-9
6.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis..Crit Care Med. 1992;20:864-874
7.
Muckart D,Bhagwanjee S..American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients.Crit Care Med. 1997;25:1789-1795
8.
Kreger Be,Craven De,Carling Pc.Gram negative bacteremia III. Reassessment of etiology, epidemiology, and ecology in 612 patients.Am J Med. 1980;68:332-8
9.
Kreger Be,Craven De,Carling Pc.Gram negative bacteremia IV. Reassessment of etiology, epidemiology, and ecology in 612 patients.Am J Med. 1980;68:344-50
10.
Bone Rc,Fischer Cj,Clemmer Tp.A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock.N Engl J Med. 1987;317:653-9
11.
Harris Rl,Musher Dm,Bloom K.Manifestations of sepsis. 1987;147:1895-1903
Slotman Gj,Burchard Kw,Williams Jj.Interaction of prostaglandins, activated completed, and granulocytes in clinical sepsis and hypotension.Surgery. 1986;99:744-50
14.
Beutler B,Cerami A.Cachectin: More than tumor necrosis factor.N Engl J Med. 1987;316:379-385
15.
Jacobs Rf,Tabor Dr..Immune cellular interactions during sepsis and septic injury.Crit Care Clinics. 1989;5:9-26
16.
Bone Rc..Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation.Crit Care Med. 1996;24:163-9
17.
Tracey Kj,Beutler B,Lowry Sf.Schock and tissue injury induced by recombinant human cachectin.Science. 1986;234:470-4
18.
Okusawa S,Gelfand Ja,Ikejima T.Interleukin 1 induces a shock like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.J Clin Invest. 1988;81:1162-72
19.
Slotman Gj,Burchard Kw,Williams Jj.Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension.Surgery. 1986;99:744-750
20.
Balk Ra,Bone Rc..The septic syndrome, definition and clinical implications.Crit Care Clinics. 1989;5:1-8
21.
Norwood Sh,Civetta Jm.Evaluating sepsis in critically ill patients.Chest. 1987;92:137-42
22.
Parker Mm,Shelhamer Jh,Bacharach Sl.Profound but reversible myocardial depression in patients with septic shock.Ann Int Med. 1984;100:483-90
23.
Wiles Jb,Cerra Fb,Siegel Jr.The systemic septic response does the organism matter?.Crit Care Med. 1980;8:55-60
24.
Parker Mm,Suffredini Af,Natanson C.Survivors of septic shock in humans develop reversible myocardial depression and ventricular dilation.Clin Res. 1986;34:413A
25.
Ognibene Fp,Parker Mm,Natanson C.Depressed left ventricular performance: Response to volume infusion in patients with sepsis and septic shock.Chest. 1988;93:903-9
26.
Cunnion Re,Parrillo Je..Myocardial dysfunction in sepsis.Crit Care Clinic. 1989;5:99-118
27.
Clowes Gha.Pulmonary abnormalities in sepsis.Surg Clin N Amer. 1974;75:993-9
28.
Kaplan Rl,Sahn Sa,Petty Tl..Incidence and outcome of respiratory distress syndrome in gram-negative sepsis.Arch Int Med. 1979;139:867-872
29.
Seidenfeld Jj,Pohl Df,Bell Rc.Incidence, site and outcome of infection in patients with the adult respiratory distress syndrome.Am Rev Respir Dis. 1986;134:12-18
30.
Zapol Wm,Snider Mt,Hill Jd.Extracorporeal membrane oxygenation in severe acute respiratory failure.JAMA. 1979;242:2193-2204
31.
Haupt MtColloidal crystalloid fluid resuscitation in shock associated with increased permeability. Basel: Karger; 1986:86-98.
32.
Velanovich V.Crystalloid versus colloid fluid resuscitation: a meta-analysis of mortality.Surgery. 1989;105:65-73
33.
Vincent Jl.Plugging the leaks? New insights into synthetic colloids.Crit Care Med. 1991;19:316-322
34.
Rackow Ec,Falk Jl,Fein Ia.Fluid resuscitation in circulatory shock: A comparison of cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hemodynamic and septic shock.Crit Care Med. 1985;11:835-843
35.
Carcillo Ja,Cunnion Re.Septic shock.Crit Care Clin. 1997;13:553-574
36.
Parrillo Je.Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy.Ann Int Med. 1990;113:227-235
37.
Ognibene Fp,Cunnion Re.Mechanisms of myocardial depression in sepsis.Crit Care Med. 1993;21:6-18
38.
Booth F. Mcl..Monitoring in resuscitation.Crit Care Clin. 1992;8:449-458
39.
Rainey Tg,Read Ca.The Pharmacologic Approach to the Critically Ill Patient. 3rd editionChernow B, ed. Baltimore, MD: Williams & Wilkins; 1994:272-290.
40.
Edwards Jd,Brown Cs,Nightingale P.Use of survivors cardiorespiratory values as therapeutic goals in septic shock.Crit Care Med. 1989;17:1098-1103
41.
Bollaert Pe,Bauer P,Audibet G.Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine resistant septic shock.Chest. 1990;98:949-953
42.
Mackenzie Sj,Kapadia F,Nimmo Gr.Adrenalin in treatment of septic shock. Effects on haemodynamics and oxygen transport.Intensive Care Med. 1991;17:36-9
43.
Shoemaker Wc,Appel Pc,Kram Hb.Prospective trial of supranormal values of survivors as therapeutic goals in high risk surgical patients.Chest. 1988;94:1176-1186
44.
Shoemaker Wc,Appel Pc,Kram Hb.Hemodynamics and oxygen transport effects of dobutamine in critically ill general surgical patients.Crit Care Med. 1986;14:1032-37
45.
Yu M,Levy Mm,Smith P.Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients. A prospective randomized, controlled study.Crit Care Med. 1993;21:830-8
46.
Tuchschmitt J,Fried J,Astic M.Evaluation of cardiac output and oxygen delivery improves outcome in septic shock.Chest. 1992;102:216-20
47.
Russel Ja,Phang Pt.The oxygen delivery/consumption controversy. Approaches to management of the critically ill.Am J Crit Care Med. 1994;149:533-7
48.
Gattinoni L,Brazzi L,Pelosi P.A trial of goal oriented hemodynamic therapy in critically ill patients.N Engl J Med.. 1995;333:1025-32
49.
Goldberg Li..Dopamine—Clinical uses of an endogenous catecholamine.N Engl J Med. 1974;291:707-10
50.
Davis Rf,Lappas Dg,Kirklin Jk.Acute oliguria after cardiopulmonary bypass: Renal functional improvement with low dose dopamine infusion.Crit Care Med. 1982;10:852-6
51.
Lindner A..Synergism of dopamine and furosemide in diuretic resistant, oliguric acute renal failure.Nephron. 1983;33:121-6
52.
Delacal Ma,Miravalles E,Pascual T.Dose-related hemodynamics and renal effects of dopamine in septic shock.Crit Care Med. 1984;12:22-5
53.
Loeb Hs,Bredakis J,Gunnar Rm.Superiority of dobutamine over dopamine in the treatment of severe heart failure.Circulation. 1977;55:375-381
54.
Boyd Jl,Stanford Gg,Chernow B.The pharmacotherapy of septic shock.Crit Care Clinics. 1989;5:133-50
55.
Gattinoni L,Brazzi L,Pelosi P.A trial of goal oriented hemodynamic therapy in critically ill patients.N Engl J Med. 1995;333:1025-1032
56.
Rudis Mi,Basha Ma,Zarowitz Bj..Is it time to reposition vasopressors and inotropes in sepsis?.Crit Care Med. 1996;24:525-37
57.
Moran Jl,O'Fathartaigh ,Peisach Ar.Epinephrine as an inotropic agent in septic shock: A dose-profile analysis.Crit Care Med. 1993;21:70-77
58.
Lipman J,Roux A,Kraus P..Vasoconstrictor effects of adrenaline in human septic shock.Anaesth Intensive Care. 1991;19:61-65
59.
Dasta Jf..Norepinephrine in septic shock. Renewed interest in an old.Drug Intell Clin Pharm. 1990;24:153-6
60.
Meadows D,Edwards Jd,Wilkens Rg.Reversal of intractable septic shock with norepinephrine therapy.Crit Care Med. 1988;16:663-6
61.
Martin C,Papazian L,Perrin G.Norepinephrine or dopamine for the treatment of hyperdynamic septic shock.Chest. 1993;103:1826-31
62.
Lucas Ce..A new look at dopamine and norepinephrine for hypodynamic septic shock.Chest. 1994;105:7-8
63.
Magrini F,Foulds R,Roberts N.Human renovascular effects of dopexamine hydro-chloride. A novel agonist of peripheral dopamine and beta2-adreno-receptors.Eur J Clin Pharmacol. 1987;32:1-4
64.
Leier Cv,Binkley Pf,Carpenter J.The cardiovascular pharmacology of dopexamine in patients with low output congestive heart failure.Am J Cardiol. 1988;62:94-99
65.
Colardyn Nf,Vandenbogaerde J,Vogelaers D.Use of dopexamine hydrochloride in patients with septic shock.Crit Care Med. 1989;17:999-1013
66.
Thompson Wj.Cyclic nucleotide phospodiesterases: Pharmacology, biochemistry and function.Pharmacol Ther. 1991;51:13-33
67.
Goene M,Pedemonte O,Baele P.Amrinone in the management of low cardiac output after open heart surgery.Am J Cardiol. 1985;56:33B-38B
68.
Vincent Jl,Domb M,Van Derlinden P.Amrinone administration in endotoxic shock.Circ Shock. 1988;25:75-83
69.
Gireir Bp,Beutler B..Effect of amrinone on tumor necrosis factor production in endotoxic shock.Circ Shock. 1992;36:200-7
70.
Jones Jl,Gengo Pj,Dodam Jr.Amrinone combined with dobutamine improved hemodynamics and oxygen delivery without down regulation of cardiac beta-adrenergic receptor density in porcine endotoxemia.Shock. 1995;3:224-34
71.
Natanson C,Danner Rl,Reilly Jm.Antibiotics versus cardiovascular support in a canine model of human septic shock.Am J Physiol. 1990;259:H1440-H1447
72.
Pizzo Pa,Hathorn Jw,Hiemenz J.A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.N Engl J Med. 1986;315:552-8
73.
Moore Rd,Lietman Ps,Smith Cr..Clinical response to aminoglycoside therapy: Importance of the ratio to peak concentration to minimum inhibitory concentration.J Infect Dis. 1987;155:93-7
74.
Summer Wr,Michael Jr,Lipsky Jj..Initial aminoglycoside levels in the critically ill.Crit Care Med. 1983;11:948-50
75.
Hassan E,Ober Jd..Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients.Antimicrob Agents Chemother. 1987;31:1855-8
76.
Niemiec Pw,Allo Md,Miller Cf..Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care.Arch Surg. 1987;122:207-12
77.
Mann Hj,Fuhs Dw,Awang R.Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis.Clin Pharm. 1987;6:148-53
78.
Paradisi F,Corti G..Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections.J Chemother. 1995;7:338-43
79.
Kluth V,Koch S,Song M..Alternative aminoglycoside dosing in neurointensive care unit (NICU) patients.Crit Care Med. 1998;26 (suppl): A99
80.
Wolfe Ta,Dasta Jf,Reilley Te.Assessment of the appropriateness of once-daily aminoglycoside dosing in surgical intensive care unit patients.Crit Care Med. 1998;26 (Suppl): A99
81.
Kapusnik Je,Hackbarth C J,Chambers Hf.Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia.J Infect Dis. 1988;158:7-12
82.
Ambrose Pg,Owens Rc,Quintiliani R.Antibiotic use in the critical care unit.Crit Care Clinics. 1998;14:283-308
83.
Klepser Me,Patel Kb,Nicolau Dp.Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1995;39:2503-10
84.
Schumer W..Steroids in the treatment of clinical septic shock.Ann Surg. 1976;184:333-41
85.
Bone Rc,Fisher Cj,Clemmer Tp.A controlled trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock.N Engl J Med. 1987;317:653-8
86.
The veterans administration systemic sepsis cooperative study group: Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis.N Engl J Med. 1987;317:659-65
87.
Moran Jl,Chapman Mj,O'Fathartaigh Ms.Hypocorticolemia and adrenocortical responsiveness at onset of septic shock.Intensive Care Med. 1995;20:489-95
88.
Soni A,Pepper Gm,Wyrwinski Pm.Adrenal insufficiency occurring during septic shock: Incidence, outcome and relationships to peripheral cytokine levels.Am J Med. 1995;98:266-71
89.
Bollaert Pe,Charpentier C,Levy B.Reversal of late septic shock with supraphysiologic doses of hydrocortisone.Crit Care Med. 1998;26:645-50
90.
Ziegler Ej,Fisher Cj,Sprung Cl.Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin.N Engl J Med. 1991;324:429-36
91.
Greenman Rl,Schein Rm,Martin Ma.A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis.JAMA. 1992;266:1097-1102
92.
McCloskey Rv,Straube Rc,Sanders C.Treatment of septic shock with human monoclonal antibody HA-1A.Ann Intern Med. 1994;121:1-5
93.
Bone Rc,Balk Ra,Fein Am.A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicentered, randomized, controlled trial.Crit Care Med. 1995;23:994-1005
94.
Cohen J,Heumann D,Glauser Mp..Do monoclonal antibodies and anticytokines still have a future in infectious disease?.Am J Med. 1995;99 (suppl 6A): 45-53
95.
Fisher Cj,Opal Sm,Dhainaut Jf.Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis.Crit Care Med. 1993;21:318-27
96.
Dhainaut Jf,Vincent Jl,Richard C.CD571, a humanized antibody to human tumor necrosis factor-a: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock.Crit Care Med. 1995;23:1461-9
97.
Abraham E,Wunderlink R,Silverman H.Efficacy and safety of a monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome.JAMA. 1995;273:934-41
98.
Reinhart K,Wiegand-Lohnert C,Grimminger F.Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody fragment MAK 195F, in patients with sepsis and septic shock: A multi-centered, randomized, placebo-controlled, dose-ranging study.Crit Care Med. 1996;24:733-42
99.
Cohen J.INTERSEPT: An international, multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis.Crit Care Med. 1996;24:1431-40
100.
Smith Al..The treatment of septic shock with immunotherapy.Pharmacotherapy. 1998;18:565-80
101.
Fisher Cj,Agosti Jm,Opal Sm.Treatment of septic shock with tumor necrosis factor receptor: Fe fusion protein.N Engl J Med. 1996;334:1697-702
102.
Abraham E,Glauser Mp,Butler T.P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicentered trial.JAMA. 1997;277:1531-8
103.
Fisher Cj,Slotman Gj,Opal Sm.Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, openlabeled, placebo-controlled multicenter trial.Crit Care Med. 1994;22:12-21
104.
Fisher Cj,Dhainaut Jf,Opal Sm..Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results of a randomized, double blind, placebo-controlled trial.JAMA. 1994;271:1826-43
105.
Opal Sm,Fisher Cj,Dhainaut Jf.Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double blind, placebo-controlled, multicentered trial.Crit Care Med. 1997;25:1115-24
106.
Cross As,Opal Sm,Parlardy Je.The efficacy of combination immunotherapy in experimental pseudomonas sepsis.J Infect Dis. 1993;167:112-8
107.
Opal Sm,Cross As,Jhung Jw.Potential hazards of combination immunotherapy in the treatment of experimental shock.J Infect Dis. 1996;173:1415-21
108.
Lundberg Js,Perl Tm,Wiblin T.Septic shock: An analysis of outcomes for patients with onset on hospital wards versus intensive care units.Crit Care Med. 1998;26:1020-24
109.
Balk Ra..Outcome of septic shock: Location, location, location.Crit Care Med. 1998;26:983-4
